← Leaderboards
Hassan Al-Ali
University Of Miami School Of Medicine
$2,291,277
Attributed
$5,452,441
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,452,441 · 4
By mechanism
R01$2,617,975 · 1
UH3$1,959,367 · 1
UG3$650,295 · 1
R41$224,804 · 1
Top collaborators
- John L Bixby7 shared
- Vance P Lemmon7 shared
- Jonathan H Schatz2 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Antonio Iavarone$20,897,912
- John L Bixby$10,654,658
- Vance P Lemmon$12,273,456
- Glen N. Barber$22,145,694
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypeScreeningPhosphotransferasesCellsKinase InhibitorMachine LearningAxonSmall MoleculeCostComplexPharmaceutical PreparationsLeadFamilyCentral Nervous System InjuryDrug TargetingIn VivoDrug DevelopmentAxon GrowthAnimal ModelClinical CandidateAnalogChronicClinical TrialsGenerations
Grant awards (9)
Essential role of the cyclin-G associated kinase (GAK) in diffuse large B-cell lymphoma progression$2,617,975
R01 · FY2025 · CA
Developing a kinase inhibitor drug to treat spinal cord injury$500,994
UH3 · FY2025 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$77,520
UH3 · FY2025 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$619,619
UH3 · FY2024 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$78,486
UH3 · FY2024 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$606,139
UH3 · FY2023 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$76,609
UH3 · FY2023 · NS · contact PI
Developing a kinase inhibitor drug to treat spinal cord injury$650,295
UG3 · FY2022 · NS · contact PI
Developing a novel platform for rapid identification of drug targets and anti-targets$224,804
R41 · FY2018 · TR · contact PI